Dorsey & Whitney Trust CO LLC Sells 262 Shares of Stryker Corporation $SYK

Dorsey & Whitney Trust CO LLC cut its stake in shares of Stryker Corporation (NYSE:SYK) by 5.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,401 shares of the medical technology company’s stock after selling 262 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Stryker were worth $1,741,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of SYK. Mid American Wealth Advisory Group Inc. bought a new stake in Stryker during the 2nd quarter valued at $26,000. Sachetta LLC increased its stake in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the period. Ridgewood Investments LLC raised its holdings in shares of Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares in the last quarter. MTM Investment Management LLC purchased a new stake in Stryker in the second quarter worth about $38,000. Finally, Ransom Advisory Ltd bought a new position in Stryker during the 1st quarter worth about $37,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.8%

Shares of NYSE:SYK opened at $359.45 on Tuesday. The business’s 50-day moving average is $371.28 and its 200 day moving average is $381.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The firm has a market capitalization of $137.46 billion, a P/E ratio of 47.61, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the company earned $2.87 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SYK shares. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Rothschild & Co Redburn started coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. UBS Group set a $408.00 target price on Stryker in a report on Monday, October 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday. Finally, Redburn Partners set a $420.00 price target on Stryker in a report on Thursday, September 18th. Thirteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $434.37.

Insiders Place Their Bets

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 522,453 shares of company stock valued at $185,516,867. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.